Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 4/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.36 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL415523 | 0.89 | CCR6 (0.54) | CCR6PAX8IDO1SLC1A3SLC1A1 | |
| SCHEMBL27944748 | 0.88 | CCR6 (0.53) | CCR6PAX8IDO1SLC1A3SLC1A1 | |
| SCHEMBL16921501 | 0.85 | CCR6 (0.49) | CCR6PAX8SLC1A3SLC1A1LTA4H | |
| SCHEMBL417676 | 0.83 | CCR6 (0.52) | CCR6PAX8IDO1SLC1A3SLC1A1 | |
| SCHEMBL29875737 | 0.82 | CCR6 (0.56) | CCR6PAX8ALDH1A1 | |
| SCHEMBL31692756 | 0.82 | LTA4H (0.43) | CCR6PAX8LTA4H | |
| SCHEMBL8501765 | 0.80 | CCR6 (0.45) | CCR6PAX8IDO1SLC1A3SLC1A1 | |
| SCHEMBL27345619 | 0.80 | CCR6 (0.56) | CCR6PAX8ALDH1A1CCKBR | |
| SCHEMBL7893066 | 0.80 | CCR6 (0.41) | CCR6PAX8IDO1SLC1A3SLC1A1 | |
| SCHEMBL417987 | 0.79 | CCR6 (0.46) | CCR6PAX8ALDH1A1SLC15A1CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022273-A1 | PROCESS FOR THE PREPARATION OF (POLY) AMINOALKYLAMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN USEFUL FOR THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-01-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022273-A1 | PROCESS FOR THE PREPARATION OF (POLY) AMINOALKYLAMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN USEFUL FOR THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENT | PTMA, NPEPPS, DNPEP | CCR6 3824/4885PAX8 2180/4885IDO1 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.